Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.079
Neutral
RSI(14)
41.356
Neutral
STOCH(KDJ)(9,3,3)
28.884
Neutral
ATR(14)
0.331
High Vlolatility
CCI(14)
-50.597
Neutral
Williams %R
74.138
Sell
TRIX(12,20)
-1.023
Sell
StochRSI(14)
64.294
Buy
Search
Unicycive Therapeutics Inc
UNCYAdd to Watchlist
5.010USD
-0.290-5.47%
Close 07-31 16:00（ET）Quotes delayed by 15 min
126.44MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-5.47%
5 Days
-7.22%
1 Month
-5.11%
6 Months
-16.08%
Year to Date
-13.17%
1 Year
+19.29%
Key Figures
5.260Open
5.290High
486.30KVolume
LossP/E TTM
0.51P/E Dynamic
--Dividend TTM
1.93%Turnover Ratio
5.300Prev. Close
4.980Low
1.64MTurnover
LossP/E Static
3.35P/B
0.00%Div Yield TTM
-86.51%ROA
11.00052wk High
0.53Volume Ratio
-37.82MNet Profit
25.24MShares
-2.2515EPS TTM
1.73Beta
-162.89%ROE
3.71052wk Low
5.85%Amplitude
100.00%Gross Margin
126.44MMarket Cap
-0.25Reward/Risk
4.56%Risk Rate
TradingKey Stock Score of Unicycive Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Unicycive Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 172 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.89.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Unicycive Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Unicycive Therapeutics Inc Highlights
StrengthsRisks
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Undervalued
The company’s latest PE is -2.23, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.56M shares, increasing 4.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.24.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
34.889
Target Price
+636.05%
Upside Space
Unicycive Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
34.889
Target Price
+636.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Unicycive Therapeutics Inc
UNCY
9
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
5.024
Sell
MA10
5.269
Sell
MA20
5.257
Sell
MA50
6.415
Sell
MA100
6.811
Sell
MA200
6.368
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Unicycive Therapeutics Inc Info
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Ticker SymbolUNCY
CompanyUnicycive Therapeutics Inc
CEOGupta (Shalabh)
Websitehttps://unicycive.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Unicycive Therapeutics Inc (UNCY)?
The current price of Unicycive Therapeutics Inc (UNCY) is 5.01.
What is the symbol of Unicycive Therapeutics Inc?
The ticker symbol of Unicycive Therapeutics Inc is UNCY.
What is the 52-week high of Unicycive Therapeutics Inc?
The 52-week high of Unicycive Therapeutics Inc is 11.00.
What is the 52-week low of Unicycive Therapeutics Inc?
The 52-week low of Unicycive Therapeutics Inc is 3.71.
What is the market capitalization of Unicycive Therapeutics Inc?
The market capitalization of Unicycive Therapeutics Inc is 126.44M.
Is Unicycive Therapeutics Inc (UNCY) currently rated as Buy, Hold, or Sell?
According to analysts, Unicycive Therapeutics Inc (UNCY) has an overall rating of Buy, with a price target of 34.89.
What is the Earnings Per Share (EPS TTM) of Unicycive Therapeutics Inc (UNCY)?
The Earnings Per Share (EPS TTM) of Unicycive Therapeutics Inc (UNCY) is -1.67.